Published in Eur J Cancer on November 04, 2010
Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4. Clin Cancer Res (2011) 1.70
Cancer/Testis Antigens as potential predictors of biochemical recurrence of prostate cancer following radical prostatectomy. J Transl Med (2011) 1.19
MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair. J Invest Dermatol (2012) 0.96
Tissue prognostic biomarkers in primary cutaneous melanoma. Virchows Arch (2014) 0.96
The melanoma-associated antigen 1 (MAGEA1) protein stimulates the E3 ubiquitin-ligase activity of TRIM31 within a TRIM31-MAGEA1-NSE4 complex. Cell Cycle (2015) 0.92
Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res (2013) 0.90
NY-ESO-1 expression in hepatocellular carcinoma: A potential new marker for early recurrence after surgery. Oncol Lett (2011) 0.89
Expression and prognostic value of MAGE-A9 in laryngeal squamous cell carcinoma. Int J Clin Exp Pathol (2014) 0.87
Construction and analysis of multiparameter prognostic models for melanoma outcome. Methods Mol Biol (2014) 0.84
Potential role of meiosis proteins in melanoma chromosomal instability. J Skin Cancer (2013) 0.83
Transketolase-like 1 ectopic expression is associated with DNA hypomethylation and induces the Warburg effect in melanoma cells. BMC Cancer (2016) 0.81
Germ cell proteins in melanoma: prognosis, diagnosis, treatment, and theories on expression. J Skin Cancer (2012) 0.80
Increased NY-ESO-1 expression and reduced infiltrating CD3+ T cells in cutaneous melanoma. J Immunol Res (2015) 0.75
Expression of novel cancer/testis antigen TMEM31 increases during metastatic melanoma progression. Oncol Lett (2017) 0.75
Genetic variants in the integrin signaling pathway genes predict cutaneous melanoma survival. Int J Cancer (2016) 0.75
Melanoma: tumor microenvironment and new treatments. An Bras Dermatol (2017) 0.75
High expression of MAGE-A9 is associated with unfavorable survival in esophageal squamous cell carcinoma. Oncol Lett (2017) 0.75
Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 23.08
Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 15.64
New models of collaboration in genome-wide association studies: the Genetic Association Information Network. Nat Genet (2007) 13.76
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med (2014) 10.69
Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 7.18
Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides. Nat Genet (2008) 6.06
Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun (2012) 4.94
Tumor antigen expression in melanoma varies according to antigen and stage. Clin Cancer Res (2006) 4.71
Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res (2011) 4.70
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention. N Engl J Med (2015) 4.64
Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol (2006) 4.51
Direct RNA sequencing. Nature (2009) 4.37
Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol (2009) 4.32
Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell (2012) 4.04
Cutaneous melanoma. Lancet (2005) 3.94
Germline mutations in BAP1 predispose to melanocytic tumors. Nat Genet (2011) 3.91
Quantification of the yeast transcriptome by single-molecule sequencing. Nat Biotechnol (2009) 3.86
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg (2005) 3.80
Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell (2013) 3.59
Recalibrating Equus evolution using the genome sequence of an early Middle Pleistocene horse. Nature (2013) 3.45
Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 3.24
Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine. Clin Cancer Res (2008) 3.24
The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol (2010) 3.02
The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. Ann Surg Oncol (2004) 2.99
What would you do if you could sequence everything? Nat Biotechnol (2008) 2.89
Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 2.88
Virtual terminator nucleotides for next-generation DNA sequencing. Nat Methods (2009) 2.83
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov (2014) 2.74
Outcomes following isolated limb infusion for melanoma. A 14-year experience. Ann Surg Oncol (2008) 2.69
Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nat Struct Mol Biol (2007) 2.62
Nevus/Melanocytoma/Melanoma: an emerging paradigm for classification of melanocytic neoplasms? Arch Pathol Lab Med (2011) 2.60
Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol (2006) 2.59
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. Eur J Cancer (2013) 2.51
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res (2012) 2.46
The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol (2005) 2.41
Patterns of lymphatic drainage from the skin in patients with melanoma. J Nucl Med (2003) 2.41
Keystone flap reconstruction of primary melanoma excision defects of the leg-the end of the skin graft? Ann Surg Oncol (2008) 2.36
Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol (2010) 2.30
False-negative sentinel node biopsy because of obstruction of lymphatics by metastatic melanoma: the value of ultrasound in conjunction with preoperative lymphoscintigraphy. Melanoma Res (2009) 2.26
An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin (2004) 2.18
BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol (2012) 2.17
Increasing tumor thickness is associated with recurrence and poorer survival in patients with Merkel cell carcinoma. Ann Surg Oncol (2012) 2.13
18F-fluorodeoxyglucose--positron emission tomography/computed tomography aids staging and predicts mortality in patients with muscle-invasive bladder cancer. Urology (2014) 2.09
Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol (2010) 2.06
Incidence of new primary melanomas after diagnosis of stage III and IV melanoma. J Clin Oncol (2013) 2.00
Melanoma patients with positive sentinel nodes who did not undergo completion lymphadenectomy: a multi-institutional study. Ann Surg Oncol (2006) 2.00
Improving doctors' letters. Med J Aust (2002) 1.98
Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95
Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol (2012) 1.95
Metastasectomy for distant metastatic melanoma: analysis of data from the first Multicenter Selective Lymphadenectomy Trial (MSLT-I). Ann Surg Oncol (2012) 1.92
Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol (2012) 1.90
BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clin Cancer Res (2014) 1.89
Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol (2009) 1.89
True single-molecule DNA sequencing of a pleistocene horse bone. Genome Res (2011) 1.88
The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. Ann Surg Oncol (2008) 1.87
Suppression of lymphoma and epithelial malignancies effected by interferon gamma. J Exp Med (2002) 1.85
Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res (2013) 1.84
Atypical spitzoid melanocytic tumors with positive sentinel lymph nodes in children and teenagers, and comparison with histologically unambiguous and lethal melanomas. Am J Surg Pathol (2009) 1.82
Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. Am J Surg Pathol (2013) 1.80
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proc Natl Acad Sci U S A (2007) 1.79
In vivo confocal microscopy for diagnosis of melanoma and basal cell carcinoma using a two-step method: analysis of 710 consecutive clinically equivocal cases. J Invest Dermatol (2012) 1.79
Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf) (2008) 1.78
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. Cancer Discov (2013) 1.75
Oncology health information quality on the Internet: a multilingual evaluation. Ann Surg Oncol (2011) 1.73
Application of pooled genotyping to scan candidate regions for association with HDL cholesterol levels. Hum Genomics (2004) 1.71
Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol Ther (2005) 1.71
EANM-EORTC general recommendations for sentinel node diagnostics in melanoma. Eur J Nucl Med Mol Imaging (2009) 1.68
State of the art, nomenclature, and points of consensus and controversy concerning benign melanocytic lesions: outcome of an international workshop. Adv Anat Pathol (2010) 1.68
Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer (2003) 1.68
Cancer/testis antigens can be immunological targets in clonogenic CD133+ melanoma cells. Cancer Immunol Immunother (2009) 1.66